Anzeige
Mehr »
Dienstag, 21.04.2026 - Börsentäglich über 12.000 News
China - das Pentagon - und dieses Unternehmen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MoBritish patients risking "fake" weight loss drugs, despite safety concerns, survey says
MoBoehringer Ingelheim launches AI centre in London
MoTrump backs psychedelics for mental health in new executive order
MoUCB to purchase Neurona and NRTX-1001 for $1.15bn
MoMSD secures EC approval for Enflonsia to prevent infant RSV infection
FrKailera makes history with record-breaking $625m IPO
FrAligos and Xiamen Amoytop sign deal for HBV therapy
FrDaiichi Sankyo and Interna partner for MNM-targeted delivery solutions
DoDevelopers back Alzheimer's drugs despite report suggesting lack of efficacy
DoLilly debuts more Foundayo data as FDA requests post-marketing trials
DoTerremoto wins $108m in Series C to drive cancer and rare disease programmes
DoNucleai and Sirona Dx to provide new proteomics solution for pharma companies
DoBoehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
MiFDA shares guide on genome editing best practices
MiAmazon launches AI drug discovery platform
MiJ&J sets the tone for Q1 earnings with strong oncology growth
MiAdcendo secures $75m in Series C funding for ADC development
MiLilly to acquire CrossBridge Bio for up to $300m
14.04.EU sees 2025 pharma export uptick amid competitiveness concerns
14.04.Pharma 5.0, Sustainability & Security: PHARMAP 2026 brings pharma's future into focus
14.04.Travere Therapeutics gains FDA approval for sparsentan in FSGS
14.04.Novo Nordisk and OpenAI forge alliance to drive speedy drug development
14.04.MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority
13.04.AbbVie bets on Chinese biopharma's pain pipeline in $745m bid
13.04.Telix and Regeneron to co-develop radiopharmaceutical therapies